Table 1: New drugs for systemic lupus erythematosus tested in clinical trials (APRIL: A proliferation-inducing ligand; BLyS: B-lymphocyte-stimulator protein; ICOS: Inducible costimulator; JAK: Janus kinase; mAb: Monoclonal antibody).
| Drug | Mechanism of action |
| Blisibimob | Inhibition of B lymphocytes (BLyS blocking) |
| Abatacept (CTLA4-Ig) | T lymphocyte costimulation blocking (CD28/B7 interaction) |
| AMG 577 | T lymphocyte costimulation blocking (by ICOS inhibition) |
| AMG 811 | IFN-γ activity blocking (anti-IFN-γ mAb) |
| Anakinra | Cytokine blockade, human recombinant IL-1 receptor antagonist |
| Anifrolumab | IFN- α activity blocking (anti-IFN-α receptor mAb) |
| Atacicept | Inhibition of B lymphocytes (BLyS-APRIL blocking) |
| CDP 7657 | Blockade of T cell co-stimulation (CD40L) |
| Epratuzumab | Inhibition of B lymphocytes (anti-CD22 mAb) |
| Glutathione | Antioxidant (N-acetylcysteine) |
| IFNa Kinoid | IFN-α vaccine |
| JAK 116439 | T lymphocyte costimulation blocking (by JAK inhibition) |
| Laquinomod | Immunomodulatory agent (synthetic tolerogen) |
| Lupizor | Immunomodulatory agent (synthetic tolerogen) |
| MEDI-570 | T lymphocyte costimulation blocking (by ICOS inhibition) |
| NNC 0152 | IFN-α activity blocking (anti-IFN-α mAb) |
| Ocrelizumab | Inhibition of B lymphocytes (anti-CD20 mAb) |
| Rapamycin | mTOR inhibition |
| Rituximab | Inhibition of B lymphocytes (anti-CD20 mAb) |
| Rontalizumab | IFN-α activity blocking (anti-IFN-α mAb) |
| Sifalimumab | IFN-α activity blocking (anti-IFN-α mAb) |
| Sirukumab | Cytokine blockade (anti-IL-6 receptor mAb) |
| SM 101 | Fcγ receptor modulation |
| Tabalumab | Inhibition of B lymphocytes (BLyS blocking) |
| Tocilizumab | Cytokine blockade (anti-IL-6 receptor mAb) |
| Vitamin D | Immunomodulatory agent |